Host: Matt Birnholz, MD

Guest: Jason M. Leider, MD, PhD

As a healthcare provider, it’s important to minimize the time between diagnosis and the beginning of therapy—and this is especially true for newly diagnosed HIV-1 patients. That’s why infectious disease specialist Dr. Moti Ramgopal explains how Symtuza can help us close the gap between those two crucial points of a HIV-1 patient’s care and begin rapid initiation.

ARV - antiretroviral drugs

Indication and Important Safety Information

INDICATION

SYMTUZA® is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults:

• who have no prior antiretroviral treatment history or
• who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least 6 months and have no known substitutions associated with resistance to darunavir or tenofovir.

BOXED WARNING: POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B

• Severe acute exacerbations of hepatitis B (HBV) have been reported in patients who are coinfected with HIV-1 and HBV and have discontinued products containing emtricitabine and/or tenofovir disoproxil fumarate (TDF) and may occur with discontinuation of SYMTUZA®.

  Action: Monitor hepatic function with both clinical and laboratory follow-up ...

Guest: Mark G. Martens MD, FACOG

Years ago only 5% of vaginal yeast infections were caused by non-albicans Candida. Today, an estimated 30% are caused by these species—and they’re becoming less responsive to fluconazole. This abridged version of Dr. Mark G. Marten's well-received conference presentation provides a useful overview of fluconazole resistance in VVC and covers such topics as:

• Trends in drug resistance in VVC
• How drug resistance happens in VVC
• Dramatic increases in fluconazole dosages
• Guidelines for treating non-albicans VVC
• Special treatment considerations for pregnant and diabetic patients

Host: Matt Birnholz, MD

Guest: Jason M. Leider, MD, PhD

To help physicians prepare for those times when they diagnose HIV-1 in treatment-naive patients, Dr. Leider shares his perspective on treating HIV-1 in patients that may have refused care at time of initial diagnosis, have not had resistance testing performed at time of diagnosis, or are unable to locate their medical records. Dr. Leider will also cover the background of the recent trial AMBER in HIV-1 treatment-naïve patients. ARV - antiretroviral drugs Indication and Important Safety Information INDICATIONSYMTUZA® is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults: who have no prior antiretroviral treatment history or who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least 6 months and have no known substitutions associated with resistance to darunavir or tenofovir. BOXED WARNING: POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B Severe acute exacerbations of hepatitis B (HBV) have been reported in patients who are coinfected with HIV-1 and HBV and have discontinued products containing emtricitabine and/or tenofovir disoproxil fumarate (TDF) and may occur with discontinuation of SYMTUZA®. Action: Monitor hepatic function with both clinical and laboratory follow-up for at least several months ...

Host: Jennifer Caudle, DO

Guest: Christie Ballantyne, MD

With the number of patients with both type 2 diabetes and established cardiovascular disease on the rise, a personalized patient approach to treating these two conditions is now more important than ever. Joining Dr. Jennifer Caudle to discuss the role of the cardiologist in managing patients with type 2 diabetes is Dr. Christie Ballantyne.

US18VZ00285 January 2019

Host: Jennifer Caudle, DO

Guest: Mikhail Kosiborod, MD

Type 2 diabetes and established cardiovascular disease continues to impact patients and more focus is now set on addressing these patients’ unmet needs. Joining Dr. Jennifer Caudle is cardiologist Dr. Mikhail Kosiborod, who discusses a more reflexive approach to disease management that aims to close this gap in care.

US18VZ00284 January 2019

Host: Jennifer Caudle, DO

Guest: Mikhail Kosiborod, MD

Guest: Christie Ballantyne, MD

Since type 2 diabetes and cardiovascular disease often go hand in hand, having a care collaboration plan in place is essential in managing these conditions. Here to discuss both the challenges and opportunities that arise when collaborating patient care are cardiologists Dr. Mikhail Kosiborod and Dr. Christie Ballantyne.

US18VZ00286 January 2019

Host: Shira Johnson, MD

Guest: Felicia Cosman, MD

Please see the Full Prescribing Information, including Boxed Warning here. At the American Society for Bone and Mineral Research (ASBMR) Congress in Montreal, Canada, Dr. Shira Johnson caught up with Dr. Felicia Cosman about treatment strategies for postmenopausal women who are at a high risk for fracture due to osteoporosis.

Host: Shira Johnson, MD

Guest: Andrew J. Laster, MD, FACR, CCD

As rheumatologists, we hear a lot about wellness these days. But what is it really referring to and what should we be focusing on when talking with patients? Learn about why wellness does matter and how it may help improve patient outcomes by listening to this show hosted by Dr. Shira Johnson and guest Dr. Andy Laster, co-president of Arthritis & Osteoporosis Consultants of the Carolinas in Charlotte, North Carolina; as well as, Member of the Board Advisors for United Rheumatology. PP-BA-US-0633 12/2018 ©Lilly USA, LLC 2018. All right reserved.

Host: Soheil Hanjani, MD, FACOG, FACS

Newly developed and refined instruments are changing the setting of hysteroscopic procedures and giving way to improved patient satisfaction and practice efficiency. Dr. Soheil Hanjani evaluates the impact of incorporating hysteroscopy into the office and shares the compelling benefits you should know about.

Host: Shira Johnson, MD

Guest: Glenn Murphy, MD

Guest: Bernadette Henrichs, PhD, CRNA, CCRN

When a patient undergoes surgery, a team of physicians and nurses work together to ensure optimal patient care before, during, and after the procedure. Host Shira Johnson, MD dives into a conversation about the importance of teamwork and neuromuscular monitoring with Dr. Glenn Murphy, anesthesiologist and professor at NorthShore University HealthSystem, and Bernadette Henrichs, professor and director of the CRNA program at the Goldfarb School of Nursing at Barnes-Jewish College. Listen in as both Dr. Murphy and Dr. Henrichs share their insights on these important topics. ANES-1188581-0000 1/17